Communiqués Azenta, Inc.

Actions

AZTA

US1143401024

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/09/2026			Varia. 5j.	Varia. 1 janv.
31,73 ^USD	+0,51 %		-4,46 %	-4,60 %

24/08	Les plus fortes baisses à la mi-séance	MT
24/08	Azenta nomme Martin Madaus, membre du conseil d'administration, au poste de PDG par intérim	MT

Communiqués

24/08	AZENTA ANNOUNCES LEADERSHIP TRANSITION	PR
05/08	Azenta : Press Release (AZTA 2026 Q3 26 ER EX 99 1)	PU
04/08	Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.	PR
22/07	Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast	PR
14/07	Artisan Industries Appoints Stephen Schwartz and Gary Doyon to Board of Directors	AQ
08/07	Azenta Completes Sale of B Medical Systems	PR
21/05	Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report	PR
06/05	Azenta : Presentation (Q2 26 Earnings Deck FINAL 05 05 26)	PU
06/05	Azenta : Press Release (Q2 26 Earnings Release 05 05 26)	PU
06/05	Azenta : Supplemental Information (Q2 26 Earnings Supplemental Letter 05 05 26)	PU
05/05	Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029	PR
29/04	Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast	PR
07/04	Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution	PR
04/03	Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities	PR
24/02	Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference	PR
09/02	Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure	PR
04/02	Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025	PR
21/01	Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast	PR
30/12	Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S.A R.L.	AQ
29/12	Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S.À R.L.	PR
10/12	Azenta : 2025 Investor Day Presentation	PU
10/12	Azenta Authorizes $250 Million Share Repurchase Program	PR
21/11	Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025	PR
12/11	Azenta Announces Fiscal 2025 Fourth Quarter and Full Year Conference Call and Webcast	PR
04/11	Azenta Life Sciences Partners with PRECEDE Foundation to Advance Early Detection of Pancreatic Cancer	PR